| Text of Recommendation | CMS should encourage Part D plans to increase access to and use of the authorized generic versions of Epclusa and Harvoni, within the authorities granted under statute. |
|---|---|
| Recommendation Number | 22-E-BL-027.01 |
| Recommendation Status | Open |
| Significant Recommendation | No |
| Recommendation Questioned Costs | $0 |
| Recommendation Funds for Better Use | $0 |
| Submitting OIG | |
|---|---|
| Report Title | Part D Plan Preference for Higher-Cost Hepatitis C Drugs Led to Higher Medicare and Beneficiary Spending |
| Report Submitting OIG-Specific Report Number | OEI-BL-21-00200 |
| Report Date Issued | Tuesday, August 9, 2022 |
| Report Agency Reviewed / Investigated | |
| Report Questioned Costs | $0 |
| Report Funds for Better Use | $0 |